Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sumitomo Signs Contract on GPCR Database with LifeSpan
January 14, 2002
- Sanofi-Synthelabo to Consider Independent Marketing: Mr Fauchet
January 14, 2002
- BULLETIN
January 14, 2002
- REGULATORY NEWS IN BRIEF
January 14, 2002
- WORLD NEWS IN BRIEF
January 14, 2002
- Lipitor Shows Highest Growth in Sales: Top 100 Drugs
January 14, 2002
- DIAGNOSTIC NEWS IN BRIEF
January 14, 2002
- Otsuka Licenses Drug for Vitreous Body Hemorrhage from ISTA
January 14, 2002
- OTC NEWS IN BRIEF
January 14, 2002
- Asahi Glass Licenses ASPEX to Diversa
January 14, 2002
- Olympus ProMarketing: Semiconductor Laser Device
January 14, 2002
- Roche Was Selected to Strengthen R&D Ability: Mr Nagayama of Chugai
January 14, 2002
- Shimadzu: Floor-Mounted Type Angiographic C-arm Support MH-300
January 14, 2002
- Dainippon Joins Tsumura in Development of Ca Antagonist
January 14, 2002
- Princeton Note Litigation Settled
January 14, 2002
- ATOL-MI Transferred to Yamashita Ikakiki
January 14, 2002
- Expert Stresses Promotion of Technology Transfer: JPMA Symposium
January 14, 2002
- Sequelae of Cerebral Hemorrhage Deleted from Ketas Indications
January 14, 2002
- To Play a Meaningful Social Role, Become Independent, and Increase Profitability
January 14, 2002
- Long-listed Drugs Account for up to 60% of Total Sales: Top 10 Companies
January 14, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…